Peer-influenced content. Sources you trust. No registration required. This is HCN.

British Medical JournalResponse to Acute Monotherapy for Major Depressive Disorder in Randomized, Placebo Controlled Trials Submitted to the US Food and Drug Administration: Individual Participant Data Analysis

Study: This meta-analysis includes 232 randomized, double-blind, placebo-controlled trials of drug monotherapy for major depressive disorder submitted to the FDA between 1979 and 2016, and comprises nearly 75,000 adult and child participants.

Conclusion: Patients with depression are likely to improve substantially from acute treatment of their depression with drug or placebo. Although the mean effect of antidepressants is only a small improvement over placebo, the effect of active drug seems to increase the probability that any patient will benefit substantially from treatment by about 15%.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form